Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CEST
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
01:08a Half of leading investors ignoring climate change - study
01:04a People line up for chance to work at Margaritaville
01:04a TERRACOM : March 2016 Quarterly Report & Appendix 5B
01:04a COLLABORATE : 02/05/2016 CL8 - Appendix 4C - March 2016 Quarterly Report
01:01a TM ROBOTICS : Partners with M.A.P Services to Sell Toshiba Machine Industrial Robots in Australia for the First Time
12:49a QANTAS AIRWAYS : Freight and australia post announce dedicated freighter fleet
12:44a DIRECTMONEY : Third quarter fy 2016 update
12:41a OXXY : Trade Notification
12:39a NINE ENTERTAINMENT : Change in substantial holding
12:39a NEW ZEALAND GOVERNMENT : strengthens air ties with India
Latest news
Advertisement
Hot News 
ANDALAS ENERGY AND POWER : Issue of Zero Coupon Loan Note
6D GLOBAL TECHNOLOGIES, INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AVOLON : sustains strong performance as fleet increases to over 400 aircraft
PETRO MATAD : Expecting "Highly Material" Compensation From Partner
HML : Director Dealing April 2016
Most Read News
07:01p TM ROBOTICS : Partners with M.A.P Services to Sell Toshiba Machine Industrial Robots in Australia for the First Time
06:00p Halliburton, Baker Hughes set to end $28 billion deal
07:04p People line up for chance to work at Margaritaville
06:04p WESTPAC BANKING : 2016 Interim Financial Results Announcement
06:12p MANCHESTER UNITED : Leicester’s fans get in the title spirit as Wes Morgan earns draw
Most recommended articles
07:08p Half of leading investors ignoring climate change - study
06:21p Norway's sovereign fund to focus on high executive pay-FT
06:09p U.S. threatens to block easing of EU car exports in TTIP talks, media report
06:00p Halliburton, Baker Hughes set to end $28 billion deal
04:59pDJTELSTRA : Plans to Return A$1.5 Billion to Shareholders